07:00 , Apr 23, 2007 |  BioCentury  |  Tools & Techniques

Ranking the kinase kingdom

After four years of work, researchers at the Wellcome Trust Sanger Institute and colleagues have elucidated the prevalence and signature of somatic mutations in human protein kinases. The findings, recently reported in Nature , have...
07:00 , Jul 31, 2006 |  BC Week In Review  |  Company News

Astex Technology, Cancer Research Technology, GlaxoSmithKline, The Institute of Cancer Research, The Wellcome Trust Ltd. deal

GSK granted licenses to the trust and the institute to three series of small molecule leads that inhibit BRAF to treat cancer. The trust and institute will optimize the leads and isolate candidates. GSK will...
07:00 , Oct 24, 2005 |  BC Week In Review  |  Company News

Astex Technology management update

Astex Technology Ltd. , Cambridge, U.K.   Business: Computational chemistry/biology   Resigned: Nigel Crockett as commercial director  ...
07:00 , May 30, 2005 |  BC Week In Review  |  Clinical News

AT7519: Phase I start

Astex will begin by mid-year an open-label, dose-escalation, U.K. and U.S. Phase I trial in patients. Astex Technology Ltd. , Cambridge, U.K.   Product: AT7519   Business: Cancer   Molecular target: Cyclin dependent kinases (CDK)...
08:00 , Mar 14, 2005 |  BC Week In Review  |  Company News

Astex Technology management update

Astex Technology Ltd. , Cambridge, U.K.   Business: Computational chemistry/biology   Hired: Neil Gallagher as director of clinical development, formerly medical science director at AstraZeneca plc  ...
08:00 , Feb 21, 2005 |  BC Week In Review  |  Company News

Astex Technology, Boehringer Ingelheim deal

Astex received its first undisclosed milestone payment from Boehringer under a 2004 deal for Astex to use its Pyramid fragment-based discovery technology to produce compounds against Boehringer's targets (see BioCentury, March 15, 2004). Astex Technology...
08:00 , Feb 14, 2005 |  BioCentury  |  Strategy

Takeda's discovery beachhead

Takeda Pharmaceutical Company Ltd. says the acquisition of protein crystallography company Syrrx Inc. will improve its discovery research efficiency while providing its first U.S. discovery research capability. A wide variety of factors contributed to Takeda's...
08:00 , Nov 1, 2004 |  BC Week In Review  |  Company News

Astex Technology, Schering deal

Astex received an undisclosed milestone under its 2003 deal with SCH. Astex is using its Pyramid fragment-based drug discovery technology to identify orally available small molecules to treat solid tumors and other diseases for SCH...
07:00 , Oct 18, 2004 |  BC Week In Review  |  Company News

Astex Technology management update

Astex Technology Ltd. , Cambridge, U.K.   Business: Computational chemistry/biology   Hired: Martin Buckland as SVP of business development, formerly VP of global business development at Elan Pharmaceuticals, a division of Elan Corp.  ...
07:00 , Jun 14, 2004 |  BC Week In Review  |  Company News

Astex Technology, Aventis deal

The companies extended their 2002 deal to obtain crystal structures of cytochrome P450 enzymes complexed to AVE compounds (see BioCentury, March 25, 2002). Astex Technology Ltd. , Cambridge, U.K.   Aventis S.A. (AVE), Strasbourg, France...